| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
90,630,000 |
| Market
Cap: |
13.92(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$129.52 - $265 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 664 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile BeiGene is a commercial-stage biotechnology company focused on developing and commercializing molecularly-targeted and immuno-oncology cancer therapeutics. Co.'s clinical-stage drug candidates include: Zanubrutinib, which is a small molecule inhibitor of Bruton's tyrosine kinase for the treatment of mantle cell lymphoma in adult patients; Tislelizumab, which is a humanized monoclonal antibody against the immune checkpoint receptor programmed cell death protein 1; Pamiparib (BGB-290), which is for the treatment of various solid tumors; and Lifirafenib, which is an investigational small molecule inhibitor with RAF monomer and dimer inhibition activities.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
100,397 |
1,200,397 |
5,371,251 |
5,588,274 |
| Total Sell Value |
$15,909,372 |
$214,459,372 |
$1,041,558,017 |
$1,085,894,829 |
| Total People Sold |
2 |
3 |
8 |
9 |
| Total Sell Transactions |
6 |
7 |
21 |
54 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Wu Xiaobin |
President & GM China |
• – – |
2020-07-15 |
4 |
AS |
$240.10 |
$650,998 |
D/D |
(2,700) |
0 |
|
7% |
|
| Wu Xiaobin |
President & GM China |
• – – |
2020-07-13 |
4 |
AS |
$220.00 |
$660,000 |
D/D |
(3,000) |
0 |
|
33% |
|
| Hillhouse Capital Management, Ltd. |
10% Owner |
– – • |
2020-07-12 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
147,035,258 |
|
33% |
|
| Oyler John |
Chief Executive Officer |
• • – |
2020-07-08 |
4 |
AS |
$196.51 |
$3,530,206 |
D/D |
(17,529) |
0 |
|
39% |
|
| Wang Xiaodong |
Chair, Scientific Advisory Brd |
– • – |
2020-07-07 |
4 |
AS |
$200.00 |
$1,200,000 |
I/I |
(6,000) |
0 |
|
42% |
|
| Huang Jane |
CMO, Hematology |
• – – |
2020-07-07 |
4 |
AS |
$200.00 |
$784,200 |
D/D |
(3,921) |
0 |
|
42% |
|
| Huang Jane |
CMO, Hematology |
• – – |
2020-07-07 |
4 |
OE |
$160.40 |
$628,928 |
D/D |
3,921 |
3,921 |
|
- |
|
| Oyler John |
Chief Executive Officer |
• • – |
2020-07-07 |
4 |
AS |
$196.82 |
$3,782,987 |
D/D |
(19,023) |
0 |
|
42% |
|
| Oyler John |
Chief Executive Officer |
• • – |
2020-07-06 |
4 |
AS |
$195.43 |
$3,422,262 |
D/D |
(17,362) |
0 |
|
41% |
|
| Wang Xiaodong |
Chair, Scientific Advisory Brd |
– • – |
2020-07-01 |
4 |
AS |
$189.19 |
$924,572 |
D/D |
(4,847) |
0 |
|
51% |
|
| Oyler John |
Chief Executive Officer |
• • – |
2020-07-01 |
4 |
S |
$191.10 |
$731,016 |
D/D |
(3,816) |
0 |
|
-51% |
|
| Liang Howard |
CFO & Chief Strategy Officer |
• – – |
2020-06-29 |
4 |
S |
$191.23 |
$57,368 |
D/D |
(300) |
0 |
|
-48% |
|
| Oyler John |
Chief Executive Officer |
• • – |
2020-06-29 |
4 |
S |
$191.56 |
$276,374 |
D/D |
(1,435) |
0 |
|
-48% |
|
| Oyler John |
Chief Executive Officer |
• • – |
2020-06-24 |
4 |
AS |
$186.11 |
$2,694,156 |
D/D |
(14,381) |
0 |
|
63% |
|
| Wang Xiaodong |
Chair, Scientific Advisory Brd |
– • – |
2020-06-23 |
4 |
AS |
$185.58 |
$1,118,298 |
I/I |
(6,000) |
0 |
|
60% |
|
| Oyler John |
Chief Executive Officer |
• • – |
2020-06-23 |
4 |
AS |
$184.56 |
$2,816,222 |
D/D |
(15,070) |
14,381 |
|
60% |
|
| Wang Xiaodong |
Chair, Scientific Advisory Brd |
– • – |
2020-06-22 |
4 |
AS |
$180.37 |
$906,673 |
D/D |
(5,000) |
0 |
|
63% |
|
| Oyler John |
Chief Executive Officer |
• • – |
2020-06-22 |
4 |
AS |
$179.58 |
$1,875,605 |
D/D |
(10,281) |
29,451 |
|
63% |
|
| Liang Howard |
CFO & Chief Strategy Officer |
• – – |
2020-06-17 |
4 |
A |
$0.00 |
$0 |
D/D |
55,887 |
172,315 |
|
- |
|
| Wu Xiaobin |
President & GM China |
• – – |
2020-06-17 |
4 |
A |
$0.00 |
$0 |
D/D |
134,147 |
1,514,562 |
|
- |
|
| Huang Jane |
CMO, Hematology |
• – – |
2020-06-17 |
4 |
A |
$0.00 |
$0 |
D/D |
48,438 |
331,902 |
|
- |
|
| Oyler John |
Chief Executive Officer |
• • – |
2020-06-10 |
4 |
AS |
$175.07 |
$157,563 |
D/D |
(900) |
0 |
|
76% |
|
| Huang Jane |
CMO, Hematology |
• – – |
2020-06-08 |
4 |
S |
$170.84 |
$107,800 |
D/D |
(631) |
0 |
|
-74% |
|
| Liang Howard |
CFO & Chief Strategy Officer |
• – – |
2020-06-08 |
4 |
S |
$170.84 |
$77,391 |
D/D |
(453) |
0 |
|
-74% |
|
| Wu Xiaobin |
President & GM China |
• – – |
2020-06-08 |
4 |
S |
$170.02 |
$478,317 |
D/D |
(2,800) |
0 |
|
-74% |
|
241 Records found
|
|
Page 8 of 10 |
|
|
5.02 (3.38%) 
